These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
574 related articles for article (PubMed ID: 9212979)
1. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor. Yu SM; Wu TS; Teng CM Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers. Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540 [TBL] [Abstract][Full Text] [Related]
4. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011 [TBL] [Abstract][Full Text] [Related]
5. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets. Lin CH; Kuo SC; Huang LJ; Huang TF; Teng CM Thromb Res; 1992 Apr; 66(1):61-73. PubMed ID: 1412184 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2. Takiguchi Y; Wada K; Nakashima M Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780 [TBL] [Abstract][Full Text] [Related]
7. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Guth BD; Müller TH Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103 [TBL] [Abstract][Full Text] [Related]
8. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig. Hirata Y; Takiguchi Y; Wada K; Matsuno H; Umemura K; Uematsu T; Nakashima M Eur J Pharmacol; 1993 Feb; 231(3):421-5. PubMed ID: 8449234 [TBL] [Abstract][Full Text] [Related]
9. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Lumley P; White BP; Humphrey PP Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074 [TBL] [Abstract][Full Text] [Related]
10. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331 [TBL] [Abstract][Full Text] [Related]
11. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Takiguchi Y; Asai F; Wada K; Nakashima M Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079 [TBL] [Abstract][Full Text] [Related]
12. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects. Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144 [TBL] [Abstract][Full Text] [Related]
13. Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist. Tanaka T; Fukuta Y; Higashino R; Sato R; Nomura Y; Fukuda Y; Ito S; Takei M; Kurimoto T; Tamaki H Eur J Pharmacol; 1998 Sep; 357(1):53-60. PubMed ID: 9788773 [TBL] [Abstract][Full Text] [Related]
14. Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; interactions with salicylic acid. Lefort J; Vargaftig BB Br J Pharmacol; 1978 May; 63(1):35-42. PubMed ID: 647162 [TBL] [Abstract][Full Text] [Related]
15. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation]. Kakushi H; Shike T; Uchida K Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):171-8. PubMed ID: 2731807 [TBL] [Abstract][Full Text] [Related]
16. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
17. Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels. Imura Y; Terashita Z; Shibouta Y; Inada Y; Nishikawa K Jpn J Pharmacol; 1990 Jan; 52(1):35-43. PubMed ID: 2137886 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of p-chlorobiphenyl on the inhibition of platelet aggregation. Ko FN; Yeh LJ; Liang HC; Kuo SC; Teng CM J Pharm Pharmacol; 1996 Apr; 48(4):395-400. PubMed ID: 8794990 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Tymkewycz PM; Jones RL; Wilson NH; Marr CG Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826 [TBL] [Abstract][Full Text] [Related]
20. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]